Shared on15 Aug 25Fair value Increased 5.56%
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.
Shared on24 Apr 25Fair value Decreased 36%
AnalystConsensusTarget has decreased revenue growth from 25.2% to 4.2%, increased future PE multiple from 5.0x to 6.5x, increased discount rate from 9.8% to 11.4% and decreased shares outstanding growth rate from 0.3% to 0.1%.